| 1 |
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony S.K. Mok, Yi-Long Lung Cancer Wu, Sumitra Thongprasert et al. · New England Journal of Medicine
Open access |
19 Aug 2009 |
8,331 |
| 2 |
A metagenome-wide association study of gut microbiota in type 2 diabetes
Junjie Qin et al. · Nature
Open access |
25 Sep 2012 |
7,088 |
| 3 |
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al. · The Lancet Oncology
|
25 Jul 2011 |
4,126 |
| 4 |
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Alice Tsang Shaw et al. · New England Journal of Medicine
Open access |
Jun 2013 |
3,429 |
| 5 |
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · The Lancet
Open access |
2 Sep 2016 |
3,404 |
| 6 |
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Tony S.K. Mok, Yi-Long Lung Cancer Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine
Open access |
6 Dec 2016 |
3,396 |
| 7 |
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S.K. Mok et al. · The Lancet
Open access258 authors |
4 Apr 2019 |
3,392 |
| 8 |
CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
R. Doug McEvoy et al. · New England Journal of Medicine
|
28 Aug 2016 |
2,096 |
| 9 |
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Lung Cancer Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology
|
14 Jan 2014 |
1,992 |
| 10 |
The gut microbiome in atherosclerotic cardiovascular disease
Zhuye Jie et al. · Nature Communications
Open access |
4 Oct 2017 |
1,737 |
| 11 |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih‐Hsin Yang et al. · The Lancet Oncology
|
11 Jan 2015 |
1,596 |
| 12 |
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Lung Cancer Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology
|
25 Sep 2017 |
1,232 |
| 13 |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean‐Charles Soria et al. · The Lancet
|
23 Jan 2017 |
1,168 |
| 14 |
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Carl Zielinski et al. · The Lancet
Open access |
19 Sep 2009 |
1,122 |
| 15 |
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al. · Cancer Cell
Open access |
2010 |
1,078 |
| 16 |
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang et al. · Clinical Cancer Research
|
30 Dec 2016 |
1,012 |
| 17 |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James Chih‐Hsin Yang, Lecia Van Dam Sequist, Sarayut Lucien Geater et al. · The Lancet Oncology
|
5 Jun 2015 |
1,002 |
| 18 |
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Jian Zhou et al. · Liver Cancer
Open access |
2020 |
848 |
| 19 |
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li, Shukui Qin, Rui‐Hua Xu et al. · The Lancet Oncology
|
13 May 2015 |
826 |
| 20 |
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
Ramón Rami–Porta, Vanessa Bolejack, John Crowley et al. · Journal of Thoracic Oncology
Open access |
24 Jun 2015 |
783 |
| 21 |
Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non—Small Cell Lung Cancer
Yanqi Huang, Zaiyi Liu, Lan He et al. · Radiology
|
27 Jun 2016 |
773 |
| 22 |
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Yi-Long Lung Cancer Wu et al. · Annals of Oncology
Open access |
23 Jun 2015 |
741 |
| 23 |
Global cancer surgery: delivering safe, affordable, and timely cancer surgery
Richard Sullivan et al. · The Lancet Oncology
Open access |
Sep 2015 |
709 |
| 24 |
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
Jian Zhou et al. · Liver Cancer
Open access |
2018 |
691 |
| 25 |
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
Simon Patrick Dearden, James Stevens, Yi-Long Lung Cancer Wu et al. · Annals of Oncology
Open access |
31 May 2013 |
663 |
| 26 |
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Marina Chiara Garassino et al. · The Lancet Oncology
Open access |
12 Jun 2020 |
624 |
| 27 |
Curcumin, Inflammation, and Chronic Diseases: How Are They Linked?
Yan He, Yuan Yue, Xi Zheng et al. · Molecules
Open access |
20 May 2015 |
611 |
| 28 |
Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography
Shengxian Tu, Jelmer Sybren Westra, Junqing Yang et al. · JACC: Cardiovascular Interventions
Open access |
Oct 2016 |
604 |
| 29 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial
Lei Chen et al. · The Lancet Oncology
|
10 Dec 2011 |
569 |
| 30 |
Diagnostic Accuracy of Angiography-Based Quantitative Flow Ratio Measurements for Online Assessment of Coronary Stenosis
Bo Xu, Shengxian Tu, Shubin Qiao et al. · Journal of the American College of Cardiology
Open access |
31 Oct 2017 |
558 |
| 31 |
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen‐Zhao Zhong et al. · The Lancet Oncology
|
22 Nov 2017 |
538 |
| 32 |
Radiomics Features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma
Bin Zhang, Jie Tian, Di Dong et al. · Clinical Cancer Research
|
9 Mar 2017 |
534 |
| 33 |
Selective autophagy of intracellular organelles: Recent research advances
Wen Li et al. · Theranostics
Open access |
9 Oct 2020 |
510 |
| 34 |
Challenges to effective cancer control in China, India, and Russia
Paul Edward Goss et al. · The Lancet Oncology
|
Apr 2014 |
510 |
| 35 |
Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
Mohsen Naghavi et al. · The Lancet
Open access2,463 authors |
Oct 2025 |
500 |
| 36 |
Central focused convolutional neural networks: Developing a data-driven model for lung nodule segmentation
Shuo Wang, Mu Zhou, Zaiyi Liu et al. · Medical Image Analysis
Open access |
30 Jun 2017 |
494 |
| 37 |
Ischemic Preconditioning Potentiates the Protective Effect of Stem Cells through Secretion of Exosomes by Targeting Mecp2 via miR-22
Yuliang Feng, Wei Chieh Huang, Wani Mashhood et al. · PLoS ONE
Open access |
18 Feb 2014 |
481 |
| 38 |
Caspase-11–mediated endothelial pyroptosis underlies endotoxemia-induced lung injury
Kwong Tai Cheng, Shiqin Xiong, Zhiming Ye et al. · Journal of Clinical Investigation
Open access |
8 Oct 2017 |
479 |
| 39 |
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Jian Zhou et al. · Liver Cancer
Open access102 authors |
2023 |
474 |
| 40 |
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony S.K. Mok, Yi-Long Lung Cancer Wu, Jin Soo Lee et al. · Clinical Cancer Research
|
Apr 2015 |
472 |
| 41 |
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Chengbei Zhou et al. · Annals of Oncology
Open access |
4 Jul 2015 |
468 |
| 42 |
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
Zhong‐Yi Dong, Jia‐Tao Zhang, Si‐Yang Maggie Liu et al. · OncoImmunology
Open access |
26 Jul 2017 |
452 |
| 43 |
YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation
Chuanzhao Zhang, Shanzhou� Huang, Hongkai Zhuang et al. · Oncogene
|
4 May 2020 |
437 |
| 44 |
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi et al. · The Lancet Oncology
|
13 Aug 2013 |
426 |
| 45 |
PI3K/Akt and HIF‑1 signaling pathway in hypoxia‑ischemia (Review)
Zhen Zhang, Yao Li, Jinhua Yang et al. · Molecular Medicine Reports
Open access |
9 Aug 2018 |
422 |
| 46 |
The prevalence of insomnia in the general population in China: A meta-analysis
Xiao-Lan Cao, Shi-Bin Wang, Bao‐Liang Zhong et al. · PLoS ONE
ReviewOpen access |
24 Feb 2017 |
419 |
| 47 |
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
Jin Li et al. · JAMA
Open access |
26 Jun 2018 |
415 |
| 48 |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Jean‐Charles Soria, Yi-Long Lung Cancer Wu, Kazuhiko Nakagawa et al. · The Lancet Oncology
|
7 Jul 2015 |
412 |
| 49 |
Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer
Rui Li, Rui Zhou, Hui Wang et al. · Cell Death and Differentiation
Open access |
8 Mar 2019 |
395 |
| 50 |
Cardiac progenitor cell-derived exosomes prevent cardiomyocytes apoptosis through exosomal miR-21 by targeting PDCD4
Jing Xiao, Yu Pan, X. H. Li et al. · Cell Death and Disease
Open access |
23 Jun 2016 |
375 |